Entrada Therapeutics (TRDA) Accumulated Depreciation & Amortization (2022 - 2025)
Historic Accumulated Depreciation & Amortization for Entrada Therapeutics (TRDA) over the last 4 years, with Q3 2025 value amounting to $10.2 million.
- Entrada Therapeutics' Accumulated Depreciation & Amortization rose 2014.88% to $10.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $10.2 million, marking a year-over-year increase of 2014.88%. This contributed to the annual value of $9.4 million for FY2024, which is 5910.86% up from last year.
- According to the latest figures from Q3 2025, Entrada Therapeutics' Accumulated Depreciation & Amortization is $10.2 million, which was up 2014.88% from $11.3 million recorded in Q2 2025.
- Over the past 5 years, Entrada Therapeutics' Accumulated Depreciation & Amortization peaked at $11.3 million during Q2 2025, and registered a low of $1.8 million during Q1 2022.
- In the last 4 years, Entrada Therapeutics' Accumulated Depreciation & Amortization had a median value of $5.9 million in 2023 and averaged $6.2 million.
- Its Accumulated Depreciation & Amortization has fluctuated over the past 5 years, first skyrocketed by 11262.46% in 2023, then surged by 2014.88% in 2025.
- Entrada Therapeutics' Accumulated Depreciation & Amortization (Quarter) stood at $3.3 million in 2022, then surged by 79.43% to $5.9 million in 2023, then soared by 59.11% to $9.4 million in 2024, then grew by 7.95% to $10.2 million in 2025.
- Its last three reported values are $10.2 million in Q3 2025, $11.3 million for Q2 2025, and $10.3 million during Q1 2025.